Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor-Positive Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02238808
What this trial is testing

See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers

Who this might be right for
Estrogen Receptor Positive Breast Cancer
AHS Cancer Control Alberta 19
Testing effectiveness (Phase 2)Looking for participantsNCT07612215
What this trial is testing

Elacestrant in Advanced Triple Positive Breast Cancer

Who this might be right for
ER Positive, HER2 Positive Breast Cancer
NYU Langone Health 50
Large-scale testing (Phase 3)Study completedNCT00066690
What this trial is testing

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Who this might be right for
Estrogen Receptor Positive Breast CancerProgesterone Receptor Positive TumorRecurrent Breast Carcinoma+5 more
ETOP IBCSG Partners Foundation 3,066
Not applicableEnded earlyNCT01346579
What this trial is testing

Biomarkers in Tissue Samples From Older Women With Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 505
Large-scale testing (Phase 3)Looking for participantsNCT05879926
What this trial is testing

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Who this might be right for
Breast Cancer
NRG Oncology 3,960
Not applicableStudy completedNCT00968214
What this trial is testing

Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 364
Testing effectiveness (Phase 2)Study completedNCT00365599
What this trial is testing

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

Who this might be right for
Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 43
Testing effectiveness (Phase 2)Study completedNCT01560416
What this trial is testing

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05607004
What this trial is testing

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Who this might be right for
Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast Cancer+1 more
Atossa Therapeutics, Inc. 87
Testing effectiveness (Phase 2)Study completedNCT01972984
What this trial is testing

Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients

Who this might be right for
Breast Cancer
Ottawa Hospital Research Institute 20
Not applicableStudy completedNCT02625935
What this trial is testing

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 206
Testing effectiveness (Phase 2)Active Not RecruitingNCT04568616
What this trial is testing

Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)

Who this might be right for
Breast CancerER Positive Breast Cancer
Dartmouth-Hitchcock Medical Center 178
Early research (Phase 1)Study completedNCT02392611
What this trial is testing

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Who this might be right for
Solid Tumors and Lymphomas
Gilead Sciences 33
Early research (Phase 1)Study completedNCT02338349
What this trial is testing

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Who this might be right for
Advanced ER+, HER2-Negative Breast Cancer
Stemline Therapeutics, Inc. 57
Post-approval studies (Phase 4)Ended earlyNCT05183828
What this trial is testing

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
University of Washington 62
Early research (Phase 1)Ended earlyNCT01149356
What this trial is testing

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 15
Early research (Phase 1)Study completedNCT01344031
What this trial is testing

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveInvasive Breast CarcinomaRecurrent Breast Carcinoma+1 more
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT01723774
What this trial is testing

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine 84
Testing effectiveness (Phase 2)UnknownNCT04236310
What this trial is testing

Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Who this might be right for
Breast CancerHER2-positive Breast CancerER-positive Breast Cancer
Ruijin Hospital 37
Testing effectiveness (Phase 2)Ended earlyNCT01430585
What this trial is testing

Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

Who this might be right for
Early Breast Cancer (Phase 2)Advanced Breast Cancer (Phase 1b)
Pfizer 14
Next Page